At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 9, 2026 at 06:01 ET
IDEAYA Biosciences announced a clinical collaboration with AstraZeneca to evaluate its investigational drug IDE849 in combination with AstraZeneca's Imfinzi for treating extensive-stage small cell lung cancer. The study will be globally sponsored by IDEAYA, with AstraZeneca supplying the drug.
- IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca on April 8, 2026.
- The collaboration will evaluate IDE849 (a DLL3 TOP1 antibody-drug conjugate) in combination with Imfinzi (durvalumab) in extensive-stage small cell lung cancer (SCLC).
- IDEAYA will sponsor the global Phase 1 clinical trial, while AstraZeneca will supply Imfinzi.
- The trial is part of a broader multi-site global Phase 1 study in DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access